Hitherto, there are no reports about soluble TIE2, FLT3-ligand (FLT3-L), endostatin, and osteoactivin levels in bone marrow blood samples of patients with different stages of myeloma disease (MGUS, NDMM, RRMM). This evidence concerns the gene FLT3LG and plasma cell myeloma.